Germany's Immatics Biotechnologies Biotechnologies has signed a licensing agreement with Danish biotech firm Genmab. They'll combine their technologies to develop several T cell-engaging bispecific immunotherapies against cancer. Under the financial terms of the deal, Immatics Biotechnologies will get a $54m initial fee, up to $550m in "milestone" payments and tiered royalties on product sales. Genmab has the option to expand the partnership if it is economically viable.
Germany's Immatics Biotechnologies has signed a licensing agreement with Danish biotech firm Genmab. They'll combine their technologies to develop several T cell-engaging bispecific immunotherapies against cancer. Under the financial terms of the deal, Immatics will get a $54m initial fee, up to $550m in "milestone" payments and tiered royalties on product sales. Genmab has the option to expand the partnership if it is economically viable.